Aim: To investigate the efficacy and safety of anticoagulant prophylaxis to prevent postoperative venous thromboembolism (VTE) during laparoscopic colorectal cancer (CRC) surgery, which is unknown in Japanese patients. Methods: We conducted this randomized controlled trial at nine institutions in Japan from 2011 to 2015. It included 302 eligible patients aged 20 years or older who underwent elective laparoscopic surgery for CRC. Patients were randomly assigned to an intermittent pneumatic compression (IPC) therapy group or to an IPC + anticoagulation therapy group. Anticoagulation therapy comprised fondaparinux or enoxaparin | 569 HATA eT Al.
| INTRODUC TI ON
Venous thromboembolism (VTE) is a common surgical complication.
The incidence of fatal VTE ranges from 0.1% to 0.8%, 1 and VTE incidence in Japan is almost the same as in Western countries. In Japan, the age-adjusted mortality rate with VTE increased from 1951 to 2000, 2 and the condition arises in 24.3% of abdominal surgery patients, including in asymptomatic cases. 3 VTE occurs in up to 20% of cancer patients and is a leading cause of death in this patient population. 4, 5 The risk of VTE differs according to cancer subgroup, treatment, and procedure, 6 with the highest risk during the initial period after a diagnosis of malignancy. 7 Thus, VTE can be considered a potentially fatal but preventable complication after major cancer surgery, 8 and prophylaxis is crucial in this setting. Of note, some of the mechanisms that give rise to cancer also can lead to VTE. For example, cancer cells can directly promote blood coagulation by generating thrombin or indirectly promote it by stimulating endothelial cells and circulating mononuclear cells to synthesize and express procoagulant factors. [9] [10] [11] Since the early 1990s, laparoscopic surgery has revolutionized the field of gastrointestinal surgery, 12 and this approach for major cancer surgery has become increasingly common. However, uniform guidelines are lacking on the use of anticoagulant prophylaxis, with little available evidence to justify its routine use in laparoscopic cancer surgery. 13, 14 A search of PubMed, PubMed Central, and Google Scholar for the terms "colon or colorectal surgery" and "VTE" and of reference lists of retrieved articles identified 20 relevant papers. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] Many of these studies were retrospective analyses that relied on database searches. They showed that VTE rates are generally lower in patients undergoing laparoscopic compared to open surgery. Of these identified studies, six had a prospective cohort design, two of which involved laparoscopic surgery. Only one study was a randomized trial, 28 which compared the effectiveness and safety of low-dose heparin versus low-molecular-weight heparin (enoxaparin) as VTE prophylaxis after colorectal surgery. In that study, VTE rates were the same in both groups, without bleeding complications or deaths from pulmonary embolism (PE), suggesting the safety and effectiveness of both anticoagulants. However, the need for anticoagulant prophylaxis to prevent VTE after laparoscopic colorectal cancer (CRC) surgery among patients of Asian descent, including Japanese patients, is unknown.
For this reason, we conducted this randomized study to investigate the clinical need for anticoagulant prophylaxis to prevent postoperative VTE in patients who undergo laparoscopic CRC surgery. University. The study protocol was registered on the website of the University Hospital Medical Information Network, Japan (protocol ID: UMIN000008435).
| ME THODS

| Study design and participants
Patients who were undergoing laparoscopic colorectal surgery who had an additional risk factor for VTE were included. As noted in the Japanese VTE guidelines, these additional risk factors include for postoperative VTE prophylaxis. Postoperative VTE was diagnosed based on enhanced multi-detector helical computed tomography. The primary endpoint was VTE incidence, including asymptomatic cases, the secondary endpoint was incidence of major bleeding, and we conducted an intention-to-treat analysis. This study is registered in UMINCTR (UMIN000008435).
Results: Postoperative VTE incidence was 5.10% with IPC therapy (n = 157) and 2.76% with IPC + anticoagulant therapy (n = 145; P = .293). We identified no symptomatic VTE cases. The major bleeding rates were 1.27% with IPC alone and 1.38% with the combination (P = .936). The overall bleeding rates were 7.69% for enoxaparin and 13.6% for fondaparinux (P = .500), and there were no bleeding-related deaths.
Conclusion: Anticoagulant prophylaxis did not reduce the incidence of VTE and the incidence of major bleeding was comparable between the two groups. Usefulness of perioperative anticoagulation was not demonstrated in this study. Pharmacological prophylaxis must be restricted in Japanese patients with higher risk of VTE.
K E Y W O R D S
anticoagulant prophylaxis, colorectal cancer, laparoscopic surgery, venous thromboembolism "thrombotic disorder, history of VTE, malignant disease, cancer chemotherapy, serious infection, central venous catheterization, longterm bed rest (more than 24 hours after surgery), leg paralysis, leg cast fixation, hormone therapy, obesity (body mass index 25 kg/m 2 or more), and varicose veins of the lower extremities." Other inclusion criteria were as follows: confirmed CRC by endoscopic examination; age ≥20 years or older; sufficient organ function, per laboratory data showing white blood cell count ≥3000/mm 3 , platelets ≥100 000/ mm 3 , total bilirubin ≤2.0 mg/dL, liver enzymes ≤100 IU/L, and serum creatinine ≤1.5 mg/dL; pre-operative d-dimer <1 μg/mL or less than twice the institution limit for excluding asymptomatic deep vein thrombosis (DVT); symptomatic DVT; and provision of written informed consent.
The exclusion criteria were as follows: active bleeding or with thrombocytopenia (platelets <10 × 10 4 /μL); risk of bleeding, including gastrointestinal ulcers, diverticulitis, colitis, acute bacterial endocarditis, uncontrolled severe hypertension, or uncontrolled diabetes mellitus; severe liver dysfunction (Child C); known hypersensitivity to unfractionated heparin, low-molecular-weight heparin, or heparinoids; history of intracranial bleeding; having undergone central cranial surgery, spine surgery, or ophthalmic surgery within 3 months before registration in the study; severe renal dysfunction (creatine clearance <20 mL/min); known hypersensitivity to contrast media; or any condition that made the patient unfit for the study, as determined by the attending physician.
The study was conducted in accordance with the ethics principles set forth in the Declaration of Helsinki, and the institutional review boards at each hospital approved the study protocol. All patients provided written informed consent before randomization. We did not collect data on the number of patients who were approached and assessed for eligibility.
| Randomization and masking
Investigators registered the patients in the study, and treatment allocation was performed preoperatively after study eligibility criteria were confirmed. Patients were randomly assigned (1:1) to either the intermittent pneumatic compression (IPC) therapy group or to the IPC + anticoagulation therapy group, using permuted blocks of four stratified by institution, gender, age, and cancer location (colon or rectum). The surgeon was informed of the patient's treatment allocation and performed the procedures. Patients and investigators were not masked regarding group assignment. The data center, which was based at the Multicenter Clinical Study Group at Osaka University, was responsible for treatment allocation, central monitoring, and statistical analyses under the supervision of the study statistician.
| VTE prophylaxis
All patients wore graduated compression stockings and received IPC. In the IPC therapy group, the attending physician used compression stockings and IPC without anticoagulant therapy for VTE prophylaxis. In the IPC + anticoagulation therapy group, the physician used compression stockings and IPC plus anticoagulant therapy. Either fondaparinux (Arixtra®; GlaxoSmithKline) or enoxaparin (Kurekisan®; Kaken Pharmaceutical Co., Ltd.) was used. The surgeon made the choice of anticoagulant. Unfractionated heparin is also recommended in the Japanese guidelines, but enoxaparin and fondaparinux only were used in this study. 33 Administration of fondaparinux or enoxaparin began 24 ± 2 hours after surgery, once hemostasis was established, following the Japanese regimen for VTE prevention. Fondaparinux (2.5 mg) was given once daily for 4-8 days, and enoxaparin (20 000 IU) was given twice daily for 7-14 days. The day of surgery was defined as day 1.
The study protocol included the approved use of epidural anesthesia as necessary. The catheter had to be removed at least 2 hours before starting the anticoagulant. The primary endpoint was the incidence of VTE, and the secondary endpoint was the incidence of major bleeding. 
| Assessment and outcome definitions
| Diagnosis of VTE
| Classification of major and minor bleeding
Bleeding was classified as major if it met ≥1 of the following conditions: fatal bleeding; retroperitoneal or intracranial bleeding; bleeding of critical organs (intraocular, adrenal, endocardial, or spinal bleeding); surgical site bleeding that required surgical intervention; or clinically overt bleeding with a decrease in hemoglobin of ≥2 g/dL, or the need for transfusion of ≥800 mL of red blood cells or whole blood within 48 hours from suspicion to bleeding symptoms. Minor bleeding was defined as bleeding that did not meet any of the major bleeding criteria.
| Statistical analysis
We planned a sample size of 150 patients per treatment group when we designed the trial. The sample size was calculated using the following assumptions to 80% power with a two-sided significance level of 0.05 to detect superiority in reduced VTE frequency.
In earlier studies, the frequency of VTE was 10.8% with fondaparinux prophylaxis and 17.6% with IPC in patients who underwent abdominal surgery. 14 In addition, VTE incidence was 1.2% in the enoxaparin group and 19.4% in the IPC group. 34 Using these data, we estimated that VTE could be anticipated to occur in 17% of patients with IPC therapy and 5% with IPC + anticoagulation therapy, allowing for a loss to follow-up of roughly 20%.
The analysis was performed on an intention-to-treat basis, using JMP Pro 13.1.0 software (SAS Institute Inc., Cary, NC. USA). To evaluate each parameter, the Chi-squared test or Fisher's exact test was used for categorical data, and Student's t test was used for continuous variables. The limit for statistical significance was set at P < .05. In the 145 patients in the latter group, anticoagulation therapy was fondaparinux for 81 and enoxaparin for 52. Another 12 patients in this group did not receive anticoagulation therapy because of postoperative hematuria (n = 1), forgotten administration (n = 1), determination by the attending physician (n = 4), or unknown reasons (n = 6). Table 1 shows the baseline clinical characteristics of the two groups, which were similar.
| RE SULTS
| Patient eligibility
| Evaluation of VTE
The VTE incidence was 5.10% with IPC therapy and 2.76% with IPC + anticoagulation (P = .382). The incidence of PE was 1.91% with IPC and 0.69% with the combination (P = .623); PE + proximal DVT occurred in 3.82% and 2.76% (P = .752), respectively; and distal DVT arose in 1.34% and 0%, respectively ( Table 2 ). The groups did not differ statistically from each other, and symptomatic VTE did not occur in this study.
| Safety outcomes
The incidence of all bleeding events was 5/157 (3.18%) for the IPC therapy group and 19/145 (13.1%) for the IPC + anticoagulation therapy group, with significant differences between groups (P = .002).
There were no deaths related to bleeding, and major bleeding occurred in two patients in each group (P = .936; Table 3 ).
Regarding anticoagulant safety, the incidence of all bleeding was 11/81 (13.6%) with fondaparinux and 4/52 (7.69%) with enoxaparin; thus, enoxaparin had fewer postoperative bleeding events than fondaparinux, but there was no statistical difference in each group.
(P = .5; Table 4 ). Most of the major bleeding was anastomotic (75%), and minor bleeding was mainly the result of melena (50%) and subcutaneous (36%) bleeding ( Table 5 ).
| D ISCUSS I ON
In this study, the incidence of VTE was 5.10% in the IPC therapy group and 2.76% in the IPC + anticoagulation therapy group, with no significant differences between them (P = .382); however, the VTE incidence rate was lower with anticoagulant use. A more detailed analysis showed that PE incidence was 2.01% and 0.69% (P = .623) without and with anticoagulant, respectively, and the incidence of PE + proximal DVT was 3.82% and 2.76% (P = .752), respectively.
These findings showed a trend toward lower incidence with use of Other studies have also reported distal DVT incidence of 1.2% with enoxaparin (low-molecular-weight heparin) and 19.4% with IPC using venography. 34 Sugimachi et al 35 reported frequencies of proximal and distal DVT with elastic stocking and IPC prophylaxis of 1.5% and 9.8%, respectively, as determined using duplex scan after laparoscopic gastrointestinal surgery. The incidence of proximal DVT in the present study was comparable to that reported previously for Japanese patients, but the incidence of distal DVT was much lower.
This distinction suggests that the detection rate for distal DVT with MDCT might be lower than with venography or duplex scan. [36] [37] [38] The addition of anticoagulation therapy reduced VTE incidence although not significantly, perhaps because of the low incidence of The Seventh American College of Chest Physicians (ACCP) guidelines consider patients with a proximal DVT risk of 4%-8% without prophylaxis to be at high risk and needing anticoagulation. 39 In the present study, despite using IPC and IPC + anticoagulant therapy, the incidence of PE + proximal DVT was 3.82% and 2.76% with each, TA B L E 1 Baseline characteristics of the patients in the study respectively. With no prevention, the incidence would be expected to be still higher. Thus, according to the ACCP guidelines, the risk of PE + proximal DVT is estimated to be high or greater in these patients. Our results suggested that preventative IPC or IPC + anticoagulant prophylaxis is essential for this patient population. Of note, anticoagulation therapy did not significantly decrease VTE frequency, and anticoagulant prophylaxis may be more appropriate for patients with a high risk of VTE and low bleeding risk.
In this study, there were no bleeding-related deaths, and the incidence of major bleeding was 1.27% and 1.38% without and with anticoagulants, respectively (P = .936). Yamaoka et al 40 reported a major bleeding incidence of 0.6% (2/362) with fondaparinux and 0.8% (5/591) with IPC among colon cancer patients (P = .715). We previously reported that the incidence of major bleeding in colon cancer patients with anticoagulant prophylaxis using fondaparinux was 0.81% (5/619; 95% CI 0.3%-1.9%). In that study, there were no bleeding-related deaths or deaths from other causes during the treatment period. 15 The major bleeding rate was similar in these reports, including the current work, and the incidence of clinically problematic bleeding was very low. These findings suggest that VTE prophylaxis using any anticoagulant can be safe with appropriate patient selection.
In the current study, we investigated VTE risk factor-related data in detail to determine their relationship with VTE. However, the number of primary outcome events was lower than expected, and fewer than expected patients had risk factors. Thus, we could not stratify patients according to higher prevalence of VTE.
The study has some limitations. First, the incidence of VTE varies with ethnicity, but this study included only patients of Japanese ancestry. Second, the number of primary outcome events was lower than expected. Finally, the duration of anticoagulation therapy differs in Japan compared to Western countries.
| CON CLUS IONS
Anticoagulant prophylaxis did not reduce the incidence of VTE and the incidence of major bleeding was comparable between the two groups. Usefulness of perioperative anticoagulation was not demonstrated in this study. Pharmacological prophylaxis must be restricted in Japanese patients with higher risk of VTE.
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